Emma Mead, PhD, Alzheimer’s Research UK Oxford Drug Discovery Institute, is focused on utilizing our understanding of genetic risk and cell signaling in glial cells to develop innovative therapeutic strategies for treating Alzheimer’s disease (AD). At the Oxford Drug Discovery Institute, researchers are particularly interested in investigating the signaling cascades that are activated in microglial cells in response to pathogenic stimuli exposure. By comprehensively understanding these cascades, researchers can identify potential targets within them that could be exploited for therapeutic purposes. One area being investigated by Dr Mead and her team is TREM2 signaling, looking beyond TREM2 itself to PLCγ2, a protective variant within the TREM2 signaling cascade, and INPP5D, a protein dysregulated in TREM2 signaling. This broader perspective helps identify additional targets within the signaling cascade that may be more amenable to drug development and offer potential therapeutic opportunities. This interview took place at The BNA 2023 International Festival of Neuroscience in Brighton, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
